Repositioning Candidate Details
| Candidate ID: | R0622 |
| Source ID: | DB04838 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Cyclandelate |
| Synonyms: | 3,3,5-Trimethylcyclohexyl mandelate; 3,5,5-Trimethylcyclohexyl amygdalate; Cyclandelate |
| Molecular Formula: | C17H24O3 |
| SMILES: | CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | A direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries. |
| CAS Number: | 456-59-7 |
| Molecular Weight: | 276.3707 |
| DrugBank Indication: | Used in the treatment of various blood vessel diseases (e.g., claudication, arteriosclerosis and Raynaud's disease) and nighttime leg cramps. |
| DrugBank Pharmacology: | Cyclandelate is in a class of drugs called vasodilators. Cyclandelate relaxes veins and arteries, which makes them wider and allows blood to pass through them more easily. |
| DrugBank MoA: | Cyclandelate produces peripheral vasodilation by a direct effect on vascular smooth muscle. Pharmacological action may be due to calcium-channel antagonism. |
| Targets: | Voltage-dependent calcium channel subunit alpha-2/delta-1 inhibitor; Liver carboxylesterase 1 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I07 | 1936 | Arteriosclerosis | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 | disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease | Details |